MORRISTOWN, N.J., Feb. 22, 2011 /PRNewswire/ -- Bayer HealthCare LLC today announced the appointment of Erica L. Mann as the new president of its Consumer Care Division, a global business based in Morristown, NJ, USA, with operations in more than 140 countries and 2009 net sales of EUR 3,080 million. Ms. Mann also becomes a member of the Bayer HealthCare Executive Committee. She will join the company effective March 14, 2011.
Ms. Mann most recently served as President and General Manager of Pfizer Nutritional Health, a global business unit with operations in more than 80 countries, and was a member of the Pfizer Senior Management Team.
Ms. Mann joined Pfizer upon its acquisition of Wyeth, where as Senior Vice President, Nutrition, she helped establish the shape and strategic direction of the new nutrition business unit, and, as Managing Director, Wyeth Australia & New Zealand, introduced a range of significant medicines and nutritionals. Ms. Mann also led Wyeth's Pharmaceutical business in South Africa for over a decade as Managing Director and Chief Executive Officer, and holds the distinction of being the first female CEO of a pharmaceutical company in that country. In addition, she has held executive positions in several industry organizations, including the South African Pharmaceutical Manufacturers' Association and Medicines Australia, as well as the International Association of Infant Food Manufacturers. Earlier in her career, she held positions of increasing responsibility at Lederle Laboratories, Johnson & Johnson and Eli Lilly & Company.
"Over the past 25 years, Ms. Mann has become noted in the industry for her strong record of delivering business results. Her outstanding experience and insights will drive Consumer Care to take advantage of the sustained growth forecast for the OTC market," said Dr. Jorg Reinhardt, Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee.
"I am confident that she will continue to drive the exceptional growth experienced under the leadership of Gary Balkema, who has made the decision to retire after 16 years with Bayer at the end of March."
The Consumer Care Division was formed in 1995 and has become the number two OTC company in the world, and the division has also seen significant growth and development of its Intendis prescription dermatology business.
Ms. Mann holds an undergraduate degree in Analytical Chemistry and a Marketing Management Diploma from the Institute of Marketing Management, Johannesburg. She resides in Hoboken, New Jersey.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 15,988 million (2009), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 53.400 employees and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.
About Bayer Consumer Care
The Consumer Care Division of Bayer HealthCare LLC, is headquartered in Morristown, N.J. Bayer's Consumer Care Division is among the largest marketers of over-the-counter medications and nutritional supplements in the world. Some of the most trusted and recognizable brands in the world today come from the Bayer portfolio of products. These include Bayer Aspirin®, Aleve®, Flanax®/Apronax®, Alka-Seltzer Plus®, Bactine®, Citracal®, RID®, Phillips' Milk of Magnesia, Midol, Alka-Seltzer®, Talcid®, Rennie®, Canesten®, Bepanthen®, Bepanthol®, One-A-Day® vitamins, Flintstones vitamins, Supradyn®, Redoxon®, Berocca®, Cal-D-Vita/Elevit®, Vital 50 Plus®, CardioAspirin. The division's prescription dermatology business operates under the name of Intendis GmbH.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
SOURCE Bayer HealthCare LLC